Aurobindo Pharma Ltd (NSE:AUROPHARMA)
₹ 1227.4 41.7 (3.52%) Market Cap: 719.18 Bil Enterprise Value: 719.74 Bil PE Ratio: 21.89 PB Ratio: 2.33 GF Score: 92/100

Full Year 2021 Aurobindo Pharma Ltd Earnings Call Transcript

May 31, 2021 / 12:30PM GMT
Release Date Price: ₹997.95 (-2.37%)
Operator

Ladies and gentlemen, good day, and welcome to Aurobindo Pharma Limited Q4 FY '21 Earnings Conference Call. (Operator Instructions) Please note that this conference is being recorded.

I now hand the conference over to Mr. Krishna Kiran. Thank you, and over to you, sir.

Krishna Kiran
Aurobindo Pharma Limited - IR Officer

Thank you. Good evening, and a warm welcome to our fourth quarter full year FY '21 Earnings Call. I am Krishna Kiran from Aurobindo Pharma Investor Relations team. We hope you have received the Q1 FY '21 financials and the press release that were sent out earlier. These are also available on our website.

With me, we have our senior management team represented by Mr. P.V. Ramprasad, Chairman, Aurobindo Pharma USA; Mr. N. Govindarajan, Managing Director; Mr. Sanjeev Dani, COO, Head of Formulations; Mr. Santhanam Subramanian, CFO; Mr. Swami Iyer, CFO, Aurobindo Pharma USA; and Mr. Arvind Bothra, Head, Investor Relations and Corporate Communication.

We will begin the call with summary highlights from the management

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot